Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Scg3 as a drug target in preparing drugs for treating vascular hyperplastic or exudative diseases

A technology for angiogenesis and ischemic diseases, applied in cardiovascular system diseases, metabolic diseases, bone diseases, etc., can solve problems such as limited understanding

Active Publication Date: 2020-06-09
李玮
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, current knowledge of the function of Scg3 is very limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Scg3 as a drug target in preparing drugs for treating vascular hyperplastic or exudative diseases
  • Application of Scg3 as a drug target in preparing drugs for treating vascular hyperplastic or exudative diseases
  • Application of Scg3 as a drug target in preparing drugs for treating vascular hyperplastic or exudative diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Example 1: Systematic identification of specific vascular endothelial ligands or factors for diabetic retinopathy

[0041] There are 378 million diabetic patients in the world, of which 93 million suffer from diabetic retinopathy (diabetic retinopathy, RD). Diabetic retinopathy is a major cause of blindness, including diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). There are 21 million diabetic macular edema patients and 17 million proliferative diabetic retinopathy patients worldwide.

[0042] Diabetic retinopathy is characterized clinically by increased vascular permeability, endothelial cell death, increased acellular capillaries, leukostasis, advanced vascular proliferation, retinal hemorrhage, and vision loss. Ranibizumab (Lucentis, ranibizumab) was approved by the US FDA in 2012 as the first anti-angiogenic drug for the treatment of DME. Clinical trials have proven that Lucentis is effective in treating DME between 21% and 37%. The la...

Embodiment 2

[0068] Example 2 Systematic identification of tumor-specific vascular endothelium and factors

[0069] Another embodiment and application example of the present invention is to apply ligandomics technology to tumor mice and systematically identify tumor-specific vascular endothelial cells. and to directly identify tumor-associated vascular endothelial factors in vivo.

[0070] Many angiogenesis factors have been proved to promote angiogenesis in tumor growth and play a decisive role in tumor growth. Many angiogenic factors and angiostatic factors have been identified, and several have been approved by the US Food and Drug Administration for anti-angiogenic therapy of tumors. However, due to various technical difficulties, all known endothelial factors have been identified individually by various methods. Therefore, it is not known how many tumor-associated vascular endothelial ligands or factors need to be identified and used in cancer therapy. This difficulty also limits o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of secretory granulin III as a drug target in preparing drugs for treating vascular hyperplastic or exudative diseases. The Scg 3 function is inhibited by adopting drug therapy, and the Scg3 can treat diabetic retinopathy, diabetic macular edema, vascular proliferation type diabetic retinopathy, vascular proliferation type senile macular degeneration, diabetic foot diseases and various tumors. Scg3 is characterized by disease specificity. Therefore, the anti-Scg3 therapy is characterized by selectively inhibiting the proliferation or exudation of diseased blood vessels with minimal side effects on normal blood vessels.

Description

[0001] This application is a divisional application. The filing date of the original application is May 6, 2016, the application number is 201610297883.6, and the title of the invention is "Application of Quantitative Ligandomics Technology in Systematic Identification of Ligands and Ligand Therapy." technical field [0002] The present invention relates to the systematic identification of disease-associated cellular ligands, age-associated cellular ligands, and receptor-specific ligands using quantitative ligandomics techniques, and using them as targets for the development of various ligand therapies. Secretogranin III (Scg3) can be used as a target to develop various drugs for ligand therapy to treat various vascular proliferative diseases, including diabetic retinopathy, diabetic macular edema, vascular proliferative diabetic retinopathy, vascular proliferation type age-related macular degeneration and various tumors. Background technique [0003] Cell ligands such as in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61P17/02A61P3/10A61P9/10A61P27/02A61P29/00A61P19/02A61P17/06A61P35/00
CPCA61K45/00A61P17/02A61P3/10A61P9/10A61P27/02A61P29/00A61P19/02A61P17/06A61P35/00
Inventor 李玮
Owner 李玮
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com